Amgen (AMGN) Accumulated Expenses (2009 - 2026)

Amgen's Accumulated Expenses history runs 18 years deep, the most recent figure standing at $16.6 billion for Q1 2026.

• In Q1 2026, Accumulated Expenses fell 3.78% year-over-year to $16.6 billion; the TTM figure through Mar 2026 stood at $16.6 billion (down 3.78% YoY), while the FY2025 annual figure was $18.5 billion, up 5.0% from the prior year.
• Accumulated Expenses was $16.6 billion for Q1 2026 at Amgen, down from $18.5 billion in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $18.5 billion in Q4 2025 to a low of $10.5 billion in Q2 2022.
• Historically, Accumulated Expenses has averaged $14.4 billion across 5 years, with a median of $14.2 billion in 2023.
• The sharpest annual moves came in 2023 and 2026: Accumulated Expenses surged 30.09% in 2023, then dropped 3.78% in 2026.
• A 5-year view of Accumulated Expenses shows it stood at $12.5 billion in 2022, then grew by 22.64% to $15.4 billion in 2023, then gained by 14.86% to $17.6 billion in 2024, then gained by 5.0% to $18.5 billion in 2025, then retreated by 10.47% to $16.6 billion in 2026.
• The last three Accumulated Expenses figures came in at $16.6 billion (Q1 2026), $18.5 billion (Q4 2025), and $16.8 billion (Q3 2025), per Business Quant data.